• News and Notes
  • Investor Relations
  • Product Pipeline
  • Therapeutic Focus
  • About Imquest

Welcome to ImQuest Life Sciences, Inc.


ImQuest Life Sciences will develop new, novel, first in class drugs for the treatment of infectious disease, cancer and inflammation.

ImQuest Life Sciences, Inc. is a leading drug discovery and development company with a highly focused strategy of developing a proprietary portfolio of novel therapeutic agents to target infectious disease and cancer. Our business model is to commercialize exciting new drugs with unique mechanisms of action both independently as well as in partnership with other pharmaceutical companies.

The ImQuest Life Sciences pipeline includes exclusive licenses to highly potent compounds for the treatment of Human Immunodeficiency Virus (HIV), Hepatitis B and Hepatitis C Virus (HBV, HCV), Influenza, including Drug- and Antibiotic-Resistant Microorganisms, and Cancer. We are strategically developing Topical Microbicides to prevent the transmission of HIV and other Sexually Transmitted Infectious (STI) organisms.


Latest News

ImQuest Life Sciences Receives FDA Approval to Initiate Clinical Trials of a Vaginal Gel for the Prevention of HIV Transmission to Women

Therapeutic Focus

Infectious Disease

Using state of the art and established in vitro models, ImQuest rapidly identifies therapeutic agents with the potential to inhibit the replication of infectious agents.


Our approach toward cancer research at ImQuest Life Sciences is based on a natural progression of identifying, characterizing and understanding the activity of an anticancer compound or biologic.

Topical Microbicides

Over the past decade, ImQuest laboratories have been at the forefront of topical microbicide development to prevent the transmission of HIV and other sexually transmitted organisms.